Mainz Biomed (MYNZ)

• Market cap: $7.28M
• 1 day: 0.63%
• 5 days: -3.05%
• 1 month: -11.67%
• 3 months: -1.85%
• 6 months: -65.66%
• Year to date: -63.02%
• 1 year: -86.92%
• 5 years: -99.6%
• 10 years: -99.6%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

Employees: 26

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

18% more funds holding

Funds holding: 11 [Q1] → 13 (+2) [Q2]

0.6% more ownership

Funds ownership: 10.58% [Q1] → 11.18% (+0.6%) [Q2]

28% less capital invested

Capital invested by funds: $754K [Q1] → $542K (-$212K) [Q2]